Terms Unconditional

Pharmacy Benefit Managers · Pharmacy Benefit Manager · Regulatory action + Private litigation

CVS Caremark

Headline

The FTC's allegation is that the rebate system was not a discount mechanism at all but a pricing engine running backwards: insulin makers competed for preferred formulary placement based on how large a rebate they…

The FTC's allegation is that the rebate system was not a discount mechanism at all but a pricing engine running backwards: insulin makers competed for preferred formulary placement based on how large a rebate they offered off the LIST price, which gave everyone in the chain a reason to push list prices UP, with the PBM keeping a cut. Patients whose costs are calculated against list price - the uninsured, the underinsured, anyone in a deductible phase - paid the inflated number while the rebate went elsewhere. Caremark settled with the FTC in July 2026 on terms that lock in up to $8.5 billion in consumer savings over ten years, unlock up to $4.5 billion more through point-of-sale rebates, delink PBM fees from list prices, and cap member insulin out-of-pocket costs at $25 per claim for up to a 34-day supply ($50 and $75 for longer supplies) unless a plan sponsor opts out in writing. That the remedy is worth billions is the measure of what the practice was worth.

  • SeveritySeverity 5 of 5. The FTC's allegation is that the rebate system was not a discount mechanism at all but a pricing engine running backwards: insulin makers competed for preferred formulary placement based on how large a rebate they…
  • Evidence tierUnassigned
  • Claims confirmed3 of 10 claims confirmed against a primary source
  • Last verified2026-08-04

Primary source. www.ftc.gov/terms/pharmacy-benefits-managers-pbm — Verified - primary source confirmed.

Last verified 96 days agoverified 96 days ago0180 days
Freshness. Last verified 96 days ago (2026-08-04); stale after 180 days.

Terms

Arbitration

The three PBMs initially COUNTERSUED the FTC challenging the underlying lawsuit's validity; after a district court let the FTC case proceed, the PBMs took the challenge to the 8th Circuit Court of Appeals (which denied their bid to halt the FTC case), and the appeal was then DISMISSED on June 30, 2026 on the parties' joint stipulation, a voluntary dismissal, not a ruling, at a point when Express Scripts had settled (Feb 2026) and Caremark (March) and Optum Rx (June) had agreed to proposed settlements — illustrating that even a well-resourced industry coalition can find it more strategic to settle than to continue contesting an FTC antitrust action.

Data sharing

MAJOR FTC ANTITRUST ACTION (filed Sept 2024; Caremark settled via a proposed consent order announced July 14, 2026, final FTC approval not confirmed as of Oct 2026): the FTC sued the THREE LARGEST pharmacy benefit managers — Caremark (CVS), Express Scripts (Cigna), and OptumRx (UnitedHealth), which together handle roughly 80% of ALL US PRESCRIPTIONS (top 6 PBMs combined handle ~95%) — alleging they engaged in ANTICOMPETITIVE AND UNFAIR REBATING PRACTICES that ARTIFICIALLY INFLATED INSULIN PRICES, by preferring higher-list-price insulin products specifically because they generate bigger manufacturer REBATES for the PBM, even when cheaper insulin options exist. CVS Caremark and the FTC jointly moved (March 2026) to withdraw from adjudication to pursue a settlement, following the template set by Express Scripts' earlier settlement (see that row) — the FTC announced the Caremark settlement on July 14, 2026 as a proposed consent order put out for 30-day public comment (up to $8.5B in consumer savings over 10 years plus up to $4.5B in point-of-sale rebate savings).

Fees and billing

This case is DIRECTLY about drug PRICING/FEES — the entire allegation is that CVS Caremark's rebate structure made insulin more expensive than it needed to be for patients nationwide.

Contacts

Privacy contact. Not recorded.

Legal notice. Not verified this pass. If publicly traded: SEC Form 10-K cover page gives the official corporate address; the Secretary of State business-entity search in the state of incorporation gives the registered agent, which must accept service. If private: the state registered agent is usually the only reliable route.

Mailing address. Not recorded.

No published channel
Paper trail: none. No published channel.

Evidence

ClaimKindSupportSources
1. The FTC alleges insulin makers competed for preferred formulary placement based on rebates off the list price.factsupportednone recorded
2. The rebate system pushed insulin list prices up.factsupportednone recorded
3. The PBM kept a cut of the rebates.factunknownnone recorded
4. Patients whose costs are calculated against list price paid the inflated price while the rebate went elsewhere.factunknown1 (1 confirmed)
5. Caremark settled with the FTC in July 2026.factsupportednone recorded
6. The settlement locks in up to $8.5 billion in consumer savings over ten years.factunsupported1 (1 confirmed)
7. The settlement unlocks up to $4.5 billion more through point-of-sale rebates.factunsupported1 (1 confirmed)
8. The settlement delinks PBM fees from list prices entirely.factunsupported1 (0 confirmed)
9. The settlement caps member insulin costs at $25 a month.factunsupported1 (0 confirmed)
10. The remedy's value measures what the practice was worth.characterizationn/anone recorded

3 of 10 claims have a confirmed source of their own.

Sources

SourceClaimTierStatusQuote
regulator · 2026-07-14
www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman
Claim 4Unassignedconfirmed“hurt patients whose out-of-pocket payments like copays and coinsurance are tied to the list price”
Quote basis: not recorded.
regulator · 2026-07-14
www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman
Claim 6Unassignedconfirmed“locks in place up to $8.5 billion in consumer savings over the next 10 years”
Quote basis: not recorded.
regulator · 2026-07-14
www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman
Claim 7Unassignedconfirmed“unlocks up to $4.5 billion in additional savings for patients over the same 10-year period from point-of-sale rebates.”
Quote basis: not recorded.
regulator · 2026-07-14
www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman
Claim 8Unassignedcorrected“delinks PBM fees from drug list prices”
Quote basis: not recorded.
regulator · 2026-07 (p
www.ftc.gov/system/files/ftc_gov/pdf/CaremarkandZinc-DecisionandOrder.pdf
Claim 9Unassignedcorrected“$25 for a prescription claim with a 0-34 days' supply;”
Quote basis: not recorded.

Source vault

Link status: Candidate - not yet fetched

DocumentLast fetchPDF
Privacy policy
caremark.com/wps/wcm/connect/privacy-policy
Not fetched yetNO (HTML only)
Terms of service
caremark.com/wps/wcm/connect/terms-of-use
Not fetched yetNO (HTML only)
Website
No URL recorded
Not fetched yet—
Primary source
https://www.ftc.gov/terms/pharmacy-benefits-managers-pbm
Verification: Verified - primary source confirmed
Not fetched yet—

Enforcement

No enforcement actions are linked to this row.

State statute

No HQ state on file, so no state statute applies by headquarters.